Literature DB >> 15639317

Alzheimer disease and Down syndrome: factors in pathogenesis.

Ira T Lott1, Elizabeth Head.   

Abstract

There is evidence to suggest that certain shared features exist in the pathogenesis of vascular disease and Alzheimer disease (AD) in the general population. In Down syndrome (DS) all adults over the age of 40 years develop sufficient neuropathology for a diagnosis of AD. However, vascular disease is not as common in DS as it is in the general population, particularly with respect to the development of atheromas. We discuss biological mechanisms and risk factors that may be common to both diseases including cholesterol metabolism, inflammation, plasminogen activator inhibitor and apolipoprotein E (Apo E). The study of individuals with DS may help to identify common pathogenic links as well as a disassociation between vascular disease and AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639317     DOI: 10.1016/j.neurobiolaging.2004.08.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  63 in total

Review 1.  γ-Secretase-regulated mechanisms similar to notch signaling may play a role in signaling events, including APP signaling, which leads to Alzheimer's disease.

Authors:  Kohzo Nakayama; Hisashi Nagase; Chang-Sung Koh; Takeshi Ohkawara
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

2.  Drugs for Alzheimer's disease.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

3.  Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Authors:  Giovanna Cenini; Amy L S Dowling; Tina L Beckett; Eugenio Barone; Cesare Mancuso; Michael Paul Murphy; Harry Levine; Ira T Lott; Frederick A Schmitt; D Allan Butterfield; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

Review 4.  The cognitive phenotype of Down syndrome: insights from intracellular network analysis.

Authors:  Avi Ma'ayan; Katheleen Gardiner; Ravi Iyengar
Journal:  NeuroRx       Date:  2006-07

5.  Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

Authors:  Daniel D Christensen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 6.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

8.  Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

Authors:  Eleonore Bayen; Katherine L Possin; Yingjia Chen; Laurent Cleret de Langavant; Kristine Yaffe
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

9.  Inositol Pyrophosphate Kinase Asp1 Modulates Chromosome Segregation Fidelity and Spindle Function in Schizosaccharomyces pombe.

Authors:  Boris Topolski; Visnja Jakopec; Natascha A Künzel; Ursula Fleig
Journal:  Mol Cell Biol       Date:  2016-11-28       Impact factor: 4.272

Review 10.  Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.

Authors:  Juan A Orellana; Pablo J Sáez; Kenji F Shoji; Kurt A Schalper; Nicolás Palacios-Prado; Victoria Velarde; Christian Giaume; Michael V L Bennett; Juan C Sáez
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.